Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Merck & Co., Inc. | EVP, General Counsel | Common Stock | 29.2K | $3.67M | $125.50 | Apr 30, 2024 | Direct |
REGENXBIO Inc. | Director | Common Stock | 14.3K | $226K | $15.81 | May 31, 2024 | Direct |
Merck & Co., Inc. | EVP, General Counsel | Stock Option (Right to Buy) | 35.2K | Apr 30, 2024 | Direct | ||
REGENXBIO Inc. | Director | Stock Options (Right to Buy) | 24.5K | May 31, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
RGNX | REGENXBIO Inc. | May 31, 2024 | 2 | $0 | 4 | Jun 4, 2024 | Director |
MRK | Merck & Co., Inc. | Apr 30, 2024 | 1 | $0 | 4 | May 2, 2024 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Feb 2, 2024 | 3 | -$4.59M | 4 | Feb 2, 2024 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Jan 22, 2024 | 1 | $2.78M | 4 | Jan 24, 2024 | EVP, General Counsel |
RGNX | REGENXBIO Inc. | Jun 2, 2023 | 2 | $0 | 4 | Jun 6, 2023 | Director |
MRK | Merck & Co., Inc. | May 4, 2023 | 1 | -$2.25M | 4 | May 5, 2023 | EVP, General Counsel |
MRK | Merck & Co., Inc. | May 2, 2023 | 1 | $0 | 4 | May 4, 2023 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Feb 3, 2023 | 3 | -$3.56M | 4 | Feb 6, 2023 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Jan 23, 2023 | 1 | $1.72M | 4 | Jan 25, 2023 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Oct 28, 2022 | 8 | -$16.4M | 4 | Nov 1, 2022 | EVP, General Counsel |
RGNX | REGENXBIO Inc. | Jun 3, 2022 | 2 | $0 | 4 | Jun 7, 2022 | Director |
RGNX | REGENXBIO Inc. | Jun 3, 2022 | 0 | $0 | 3 | Jun 7, 2022 | Director |
MRK | Merck & Co., Inc. | May 3, 2022 | 1 | $0 | 4 | May 5, 2022 | EVP, General Counsel |
MRK | Merck & Co., Inc. | Feb 24, 2022 | 1 | $1.35M | 4 | Feb 28, 2022 | EVP, General Counsel |